PDCD1 and hypophysitis: Lastly, the prevalence of hypophysitis in patients treated with anti-PD-1 and anti-PD-L1 increases when these ICIs are associated with anti-CTLA-4 antibodies or when patients have pre-existing autoimmune or inflammatory disorders.